N@N

BioElectronics Corporation: BioElectronics Announces Menstrual Pain Clinical Study

^{Published on 2009-03-17 07:17:42, Last Modified on 2009-03-17 07:18:30 - Market Wire}
 

FREDERICK, MD--(Marketwire - March 17, 2009) - BioElectronics Corp. (PINKSHEETS: [ BIEL ]), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the organization of a new clinical study to demonstrate the efficacy of its Allay Menstrual Pain Therapy product. The randomized double-blind, placebo and positive controlled trial involving approximately 120 adult female women began in early March with data expected in approximately 60 days. Barry L. Eppley, M.D., D.M.D., of Indianapolis, Indiana and Sheena Kong, M.D., of San Francisco, California, are conducting the study.

"While there are literally hundreds of peer-reviewed, scientific studies on the effects of Pulsed Electromagnetic Field Therapy (PEMF) on a variety of physical ailments and conditions, to our knowledge there have been none conducted directly related to the alleviation of menstrual pain and discomfort," commented Dr. Barry Eppley. "It is estimated that as many as 60% to 70% of women suffer from pain during menstruation, with millions of these women having pain severe enough to restrict their daily activities. BioElectronics Corporations' version of PEMF technology offers strong promise for the reduction or alleviation of such discomfort."

In an initial pilot study, conducted by Dr. Eppley, 23 female patients with problematic menstrual issues used the Allay product continuously for five days when the onset of their menstrual period was evident, achieved an overall pain reduction on a daily basis of between 31% and 73%.

About BioElectronics Corporation

BioElectronics Corporation is the maker of the Allay™ Menstrual Pain Therapy, the RecoveryRx™ Therapy, ActiPatch® Therapy, and the HealFast™ Therapy for veterinary applications, ([ http://www.healfasttherapy.com ]). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international agencies. [ http://www.bioelectronicscorp.com ]

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.